Skip to content

Study · Non-randomized trial · 1986

7 results

The effect of intravenous, subcutaneous, and intranasal GH-RH analog, [Nle27]GHRH(1-29)-NH2, on growth hormone secretion in normal men: dose-response relationships.

Vance ML, Evans WS, Kaiser DL, Burke RL, Rivier J, Vale W, Thorner MO

Clinical pharmacology and therapeutics1 Dec 1986Cited by 17 (Europe PMC)

PMID3096623 (opens in a new tab)DOI10.1038/clpt.1986.237 (opens in a new tab)PepBankPUB-03096623
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In normal men, the GH-RH analog [Nle27]GH-RH(1-29)-NH2 stimulated GH in a dose-responsive manner by the intravenous, subcutaneous and intranasal routes.

    In plain wordsIn normal men, this GHRH analog raised growth hormone in a dose-related way when given into a vein, under the skin or in the nose.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH stimulation, dose-response across routes
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intravenous, subcutaneous and intranasalAs given in this study (human).

    Source sentences

    Summary
    GH stimulation occurred in a dose-responsive manner after all three routes of administration.
    1 context sentence
    Summary · context
    A 29 amino acid analog of growth hormone releasing hormone (GH-RH)-40 was given intravenously, subcutaneously, and intranasally to normal men to determine its effectiveness in stimulating growth hormone (GH) release.
  2. 02HumanNon-randomized trialEfficacy outcome

    In normal men, a tenfold higher subcutaneous dose than intravenous dose of the analog was needed for a comparable GH response.

    In plain wordsIn normal men, ten times more analog was needed under the skin than in a vein to get a similar growth hormone rise.

    Peptide
    Sermorelin
    Outcome
    DecreaseRelative potency of subcutaneous versus intravenous dose
    Study

    n: not reported in source

    Comparator
    Intravenous administration
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    A tenfold higher subcutaneous dose was required to stimulate a comparable amount of GH secretion as compared with intravenous administration
    1 context sentence
    Summary · context
    A 29 amino acid analog of growth hormone releasing hormone (GH-RH)-40 was given intravenously, subcutaneously, and intranasally to normal men to determine its effectiveness in stimulating growth hormone (GH) release.
  3. 03HumanNon-randomized trialEfficacy outcome

    In normal men, a thirtyfold higher intranasal than intravenous dose of the analog gave only about one fifth of the GH release.

    In plain wordsIn normal men, a nose dose 30 times larger gave only about one fifth of the growth hormone release of a vein dose.

    Peptide
    Sermorelin
    Outcome
    DecreaseRelative potency of intranasal versus intravenous dose
    Study

    n: not reported in source

    Comparator
    Intravenous administration
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    a thirtyfold higher intranasal than intravenous dose was required to stimulate approximately one fifth the amount of GH release.
    1 context sentence
    Summary · context
    A 29 amino acid analog of growth hormone releasing hormone (GH-RH)-40 was given intravenously, subcutaneously, and intranasally to normal men to determine its effectiveness in stimulating growth hormone (GH) release.
  4. 04HumanNon-randomized trialEfficacy outcome

    In normal men, GH secretion after 1 microgram/kg Nle27 GH-RH was comparable to that after 1 microgram/kg GH-RH-40.

    In plain wordsIn normal men, the analog gave a growth hormone rise comparable to that of the full-length GHRH-40 at the same dose.

    Peptide
    Sermorelin
    Outcome
    No significant changeGH secretion versus GH-RH-40 at 1 microgram/kg
    Study

    n: not reported in source

    Comparator
    GH-RH-40
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    For comparison, one dose of GH-RH-40, 1 microgram/kg, was administered intravenously. GH secretion after 1 microgram/kg GH-RH-40 and 1 microgram/kg Nle27 GH-RH was comparable between the two groups of subjects.
    1 context sentence
    Summary · context
    A 29 amino acid analog of growth hormone releasing hormone (GH-RH)-40 was given intravenously, subcutaneously, and intranasally to normal men to determine its effectiveness in stimulating growth hormone (GH) release.
  5. 05HumanNon-randomized trialPharmacokinetics

    In normal men, GH stimulation began within 5 minutes of intravenous and within 10 minutes of subcutaneous and intranasal analog, with peak GH within 30 minutes.

    In plain wordsIn normal men, growth hormone began to rise within 5 to 10 minutes of the analog and peaked within 30 minutes.

    Peptide
    Sermorelin
    Outcome
    Not applicableTime to GH onset and peak
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Endocrine and hormones
    Studied dose
    Dose not stated · intravenous, subcutaneous and intranasalAs given in this study (human).

    Measurements

    onset of GH stimulation
    ≤ 5 min
    intravenous
    onset of GH stimulation
    ≤ 10 min
    subcutaneous and intranasal
    time to peak GH
    ≤ 30 min
    all routes

    Source sentences

    Summary
    Stimulation of GH secretion by Nle27 GH-RH occurred within 5 minutes of intravenous and within 10 minutes of subcutaneous and intranasal administration; peak GH levels were observed within 30 minutes.
    1 context sentence
    Summary · context
    A 29 amino acid analog of growth hormone releasing hormone (GH-RH)-40 was given intravenously, subcutaneously, and intranasally to normal men to determine its effectiveness in stimulating growth hormone (GH) release.
  6. 06HumanNon-randomized trialPharmacokinetics

    In normal men, GH levels declined and returned to near baseline 2 hours after the analog.

    In plain wordsIn normal men, growth hormone levels fell back to near baseline about 2 hours after the analog.

    Peptide
    Sermorelin
    Outcome
    DecreaseReturn of GH to baseline
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    time to near-baseline GH
    2 hours
    after administration

    Source sentences

    Summary
    GH levels declined and returned to near baseline levels 2 hours after administration of the analog.(ABSTRACT TRUNCATED AT 250 WORDS)
    1 context sentence
    Summary · context
    A 29 amino acid analog of growth hormone releasing hormone (GH-RH)-40 was given intravenously, subcutaneously, and intranasally to normal men to determine its effectiveness in stimulating growth hormone (GH) release.
  7. 07HumanNon-randomized trialSafety outcome

    In normal men, the analog stimulated GH secretion by intravenous, subcutaneous and intranasal routes without adverse effect.

    In plain wordsIn normal men, the analog raised growth hormone by all three routes with no reported adverse effect.

    Peptide
    Sermorelin
    Outcome
    No significant changeAdverse effects
    Study

    n: not reported in source

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · intravenous, subcutaneous and intranasalAs given in this study (human).

    Source sentences

    Summary
    This peptide stimulates GH secretion when given by the intravenous, subcutaneous, and intranasal routes without adverse effect.
    1 context sentence
    Summary · context
    A 29 amino acid analog of growth hormone releasing hormone (GH-RH)-40 was given intravenously, subcutaneously, and intranasally to normal men to determine its effectiveness in stimulating growth hormone (GH) release.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.